![]() |
市場調查報告書
商品編碼
2021512
精準發酵原料市場預測至2034年-按產品類型、原料、發酵製程、應用、最終用戶及地區分類的全球分析Precision Fermentation Ingredients Market Forecasts to 2034 - Global Analysis By Product Type, Raw Material, Fermentation Process, Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球精細發酵原料市場規模將達到 38 億美元,並在預測期內以 15.6% 的複合年成長率成長,到 2034 年將達到 122 億美元。
精準發酵原料是指透過程式化調控酵母、細菌和絲狀真菌等微生物宿主,並在商業規模的生物圖器中進行發酵,從而表達特定目標分子,進而生產生物活性化合物、蛋白質、脂質、維生素、酵素、香料、色素和功能性纖維。這使得生產用於食品飲料、醫藥和化妝品領域的原料成為可能,這些原料在功能上與傳統的動物源性或合成替代品完全相同,但無需使用動物性成分,且具有更高的土地利用效率。
對替代蛋白質的需求
食品生產商對非動物性功能性蛋白質的需求激增,他們希望找到性能與傳統乳製品和雞蛋媲美的產品,這加速了微發酵原料的商業化進程。像Perfect Day和Remilk這樣的公司正在展示消費者認可的微發酵乳清蛋白和酪蛋白,這些產品可用於冰淇淋、優格和烘焙點心。品牌永續性計畫和消費者對蛋白質多樣化的偏好,也促使企業更加關注微發酵原料的供應。
新食品的監管核准
根據歐洲食品安全局 (EFSA) 和各國食品安全機構的監管框架,新食品產品需要經過漫長的核准,導致微發酵原料類產品上市時間延長數年。此類產品必須進行廣泛的毒性測試並記錄成分特徵,這是新原料安全文件的強制性要求。這顯著增加了原料註冊成本,並將產品上市時間延長至Start-Ups公司資金籌措期之後。
醫藥級生產
藥品和生物製藥的生產應用代表高附加價值的成長機會。這是因為微發酵平台已展現出以與傳統合成路線相媲美的成本和純度生產藥物活性成分、重組蛋白和稀有生物活性分子的能力。對發酵衍生治療性蛋白質的生物製藥契約製造需求正在催生高利潤的生產契約,這有助於抵消雙用途發酵設施營運商在食品原料規模化生產方面的投資。
消費者對基因改造生物的看法
消費者對微發酵生產流程與基因改造生物(GMO)之間關聯的擔憂,對市場接受度構成威脅,使得含有微發酵成分的食品的零售標籤策略和品牌定位變得複雜。儘管基因改造作物和發酵衍生成分在監管方面有所區別,但公眾認知上的差異以及生物技術領域媒體報告的混亂,造成了品牌風險。因此,在微發酵成為主流食品應用之前,需要投入大量資金進行消費者教育,以克服這些風險。
新冠疫情暴露了傳統動物性原料供應鏈的諸多脆弱性,加速了食品生產商對微發酵作為供應鏈韌性策略的興趣。疫情期間永續發展意識的增強以及投資者對替代食品技術的熱情,擴大了微發酵領域的資金籌措和商業性夥伴關係。為實現後疫情時代食品體系轉型而進行的投資,持續為微發酵原料在大眾市場食品應用領域的商業化注入大量資金。
在預測期內,微發酵產生的風味和芳香化合物細分市場預計將成為最大的細分市場。
在預測期內,微發酵生產的風味和芳香化合物預計將佔據最大的市場佔有率。這主要歸功於現有食品法規結構內發酵風味化合物的商業性先例,以及目標芳香分子與傳統天然風味萃取方法和合成風味合成方法相比所展現出的成本競爭力。隨著品牌尋求能夠標註為「天然來源」且供應鏈更清潔的風味成分,以取代傳統萃取方法,領先的風味生產商正積極尋求微發酵供應夥伴關係。
在預測期內,微生物宿主生物體細分市場預計將呈現最高的複合年成長率。
在預測期內,微生物宿主生物體領域預計將呈現最高的成長速度。這主要得益於合成生物學工具包的擴展,這些工具包能夠設計出具有更高產量、更廣泛的基材可用性和更強的抗逆性的新型微生物底盤。這將降低發酵生產成本,並擴大目標原料類別的商業性可行性。對專有微生物菌株開發的投資正在帶來競爭優勢,這推動了精準發酵平台公司在研發方面的大量投入。
在預測期內,北美預計將佔據最大的市場佔有率。這是因為美國擁有全球最成熟的精準發酵投資生態系統,孕育了 Perfect Day、Ginkgo Bioworks 和 Amyris 等主要企業。該生態系統得益於豐富的創業投資投資、聯邦政府對生物經濟研究的資助以及完善的食品技術監管管道,這些都為面向國內和出口市場的原料商業化生產提供了支持。
在預測期內,亞太地區預計將呈現最高的複合年成長率。這主要得益於中國、印度和新加坡對替代蛋白需求的快速成長,而這種成長又受到都市化、蛋白質價格挑戰以及政府糧食安全投資計劃的推動;此外,國內精細發酵Start-Ups的活躍度不斷提高,以及大型食品公司加大對區域消費品發酵衍生原料供應鏈夥伴關係的投資,也是推動亞太地區成長的主要因素。
According to Stratistics MRC, the Global Precision Fermentation Ingredients Market is accounted for $3.8 billion in 2026 and is expected to reach $12.2 billion by 2034 growing at a CAGR of 15.6% during the forecast period. Precision fermentation ingredients refer to bioactive compounds, proteins, fats, vitamins, enzymes, flavors, pigments, and functional fibers produced through the programmatic engineering of microbial host organisms including yeast, bacteria, and filamentous fungi to express specific target molecules from genetic blueprints using bioreactor fermentation processes at commercial scale, enabling animal-free and land-efficient production of ingredients functionally identical to conventional animal-derived or synthetic counterparts for food, beverage, pharmaceutical, and cosmetic applications.
Alternative Protein Demand
Surging alternative protein demand from food manufacturers seeking animal-free functional protein ingredients with conventional dairy and egg performance characteristics is accelerating precision fermentation ingredient commercial scale-up as companies including Perfect Day and Remilk demonstrate consumer-acceptable precision-fermented whey and casein proteins for ice cream, yogurt, and baked goods applications. Brand sustainability commitments and consumer protein diversification preferences are generating substantial enterprise procurement interest in precision fermentation supply agreements.
Regulatory Novel Food Approval
Regulatory novel food approval timelines under European EFSA and various national food safety authority frameworks create multi-year commercialization delays for precision fermentation ingredient categories entering markets where novel ingredient safety dossier requirements mandate extensive toxicological studies and compositional characterization documentation that substantially increase ingredient registration costs and extend market entry timelines beyond startup funding horizons.
Pharmaceutical Grade Production
Pharmaceutical and biotherapeutic production applications represent a premium-value growth opportunity as precision fermentation platforms demonstrate capabilities for producing active pharmaceutical ingredients, recombinant proteins, and rare bioactive molecules at costs and purities competitive with conventional synthesis routes. Biopharmaceutical contract manufacturing demand for fermentation-derived therapeutic proteins is generating high-margin production contracts that cross-subsidize food ingredient scale-up investments for dual-use fermentation facility operators.
Consumer GMO Perception
Consumer perception concerns about genetically modified organism associations with precision fermentation production processes represent a market acceptance threat that complicates retail labeling strategies and brand positioning for food products containing precision-fermented ingredients. Despite regulatory distinctions between GMO crops and fermentation-derived ingredients, public awareness gaps and media conflation of biotechnology categories create brand risk that requires significant consumer education investment to overcome for mainstream food applications.
COVID-19 demonstrated critical vulnerabilities in conventional animal-derived ingredient supply chains that accelerated food manufacturer interest in precision fermentation as a supply chain resilience strategy. Pandemic-era sustainability awareness and investor enthusiasm for food technology alternatives elevated precision fermentation funding and commercial partnerships. Post-pandemic food system transformation investment continues to channel substantial capital toward precision fermentation ingredient commercialization for mass market food applications.
The precision-fermented flavors & aroma compounds segment is expected to be the largest during the forecast period
The precision-fermented flavors & aroma compounds segment is expected to account for the largest market share during the forecast period, due to established commercial precedent for fermentation-derived flavor compounds within existing food regulatory frameworks and demonstrated cost competitiveness with conventional natural flavor extraction and synthetic flavor synthesis routes for target aroma molecules. Major flavor houses are actively sourcing precision fermentation supply partnerships as brands seek natural-positioned flavor ingredients with cleaner supply chain documentation than conventional extraction alternatives.
The microbial host organisms segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the microbial host organisms segment is predicted to witness the highest growth rate, driven by expanding synthetic biology toolkits enabling engineering of novel microbial chassis with enhanced production yields, broader substrate utilization, and improved stress tolerance characteristics that reduce fermentation production costs and expand the commercial feasibility of target ingredient categories. Investment in proprietary microbial strain development is creating competitive advantages that drive significant R&D expenditure among precision fermentation platform companies.
During the forecast period, the North America region is expected to hold the largest market share, due to the United States hosting the world's most mature precision fermentation investment ecosystem with leading companies including Perfect Day, Ginkgo Bioworks, and Amyris, supported by strong venture capital availability, federal bioeconomy research funding, and established food technology regulatory pathways that enable commercial scale ingredient production for domestic and export markets.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly growing alternative protein demand in China, India, and Singapore driven by urbanization, protein affordability challenges, and government food security investment programs, combined with increasing domestic precision fermentation startup activity and major food company investment in fermentation-derived ingredient supply chain partnerships for regional consumer goods applications.
Key players in the market
Some of the key players in Precision Fermentation Ingredients Market include Perfect Day, Remilk, New Wave Foods, Motif FoodWorks, Change Foods, Imagindairy, Formo, Bond Pet Foods, MycoTechnology, Ginkgo Bioworks, Zymergen (Ginkgo), Amyris, Bolt Threads, Modern Meadow, Melt&Marble, and Nourish Ingredients.
In February 2026, Perfect Day secured a major supply agreement with a leading global ice cream manufacturer to provide precision-fermented whey protein for animal-free dairy product reformulation across European markets.
In January 2026, Amyris expanded its precision fermentation ingredient portfolio with commercial-scale production of fermentation-derived squalene for cosmetics and pharmaceutical applications, reducing dependency on shark liver oil sourcing.
In November 2025, Formo received European novel food approval for its precision-fermented casein protein, enabling commercial launch of animal-free European-style cheeses through specialty food retail distribution channels.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.